¼¿ï´ëÇб³ ¾î¸°À̺´¿ø ´ëÇѺ´¸®ÇÐȸ 2019³âµµ Á¦3Â÷ ¿¬¼ö±³À°(À¯¹æº´¸®) : 2019-11-23±³À°ÀÏÀÚ : 2019-11-23
±³À°Àå¼Ò : ¼¿ï´ëÇб³ ¾î¸°À̺´¿ø ÀÓ»ó Á¦1,2°ÀǽÇ
±³À°ÁÖÁ¦ :
2019³âµµ Á¦3Â÷ ¿¬¼ö±³À°(À¯¹æº´¸®)ÁÖÃÖ±â°ü : ´ëÇѺ´¸®ÇÐȸ
´ã´çÀÚ : ´ëÇѺ´¸®ÇÐȸ
¿¬¶ôó : 02-795-3094
À̸ÞÀÏ :
ksphe@kams.or.kr ±³À°Á¾·ù : º´¸®°ú
Âü¼®¿¹»óÀοø : 200¸í
Èñ¸ÁÆòÁ¡ : 5Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 5 ½Ã°£ 30ºÐ
¼¼ºÎ¼ö°·á : 110,000¿ø
ºñ°í 1. ȸ¿ø 1) ¹Ì³³È¸ºñ ¾ø´Â °æ¿ì »çÀüµî·Ï Àü¹®ÀÇ 50,000 Àü°øÀÇ30,000 ÇöÀåµî·Ï Àü¹®ÀÇ 60,000 Àü°øÀÇ40,000 2) ¹Ì³³È¸ºñ ÀÖ´Â °æ¿ì »çÀüµî·Ï Àü¹®ÀÇ 70,000 Àü°øÀÇ 50,000 ÇöÀåµî·Ï Àü¹®ÀÇ 80,000 Àü°øÀÇ 60,000 2. º´¸®ÇÐȸ ȸ¿øÀÌ ¾Æ´Ñ °æ¿ì »çÀüµî·Ï Àü¹®ÀÇ 100,000 À¯°ü¾÷ü ¶Ç´Â ´Üü ¼Ò¼Ó ºñȸ¿ø 100,000 Àü°øÀÇ/Á¶±³/´ëÇпø»ý 50,000 ÇöÀåµî·Ï Àü¹®ÀÇ 110,000 À¯°ü¾÷ü ¶Ç´Â ´Üü ¼Ò¼Ó ºñȸ¿ø 110,000 Àü°øÀÇ/Á¶±³/´ëÇпø»ý 60,000
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 11-23 ÀÓ»óÁ¦1,2°ÀÇ½Ç 10:00~10:30 Normal Histology & Pathology Reporting of Breast Cancer ÀÌÁö½Å(Àü³²ÀÇ´ë)
±³À°½Ã°£ 11-23 ÀÓ»óÁ¦1,2°ÀÇ½Ç 10:30~11:10 Biomarkers in Breast Cancer ¹Ú¼Ò¿¬(¼¿ïÀÇ´ë)
±³À°½Ã°£ 11-23 ÀÓ»óÁ¦1,2°ÀÇ½Ç 11:10~11:50 Ductal Proliferative Lesion ¹è¿µ°æ(¿µ³²ÀÇ´ë)
±³À°½Ã°£ 11-23 ÀÓ»óÁ¦1,2°ÀÇ½Ç 13:10~13:50 Triple Negative Breast Cancer ¼º¼øÈñ(ÀÌÈÀÇ´ë)
±³À°½Ã°£ 11-23 ÀÓ»óÁ¦1,2°ÀÇ½Ç 13:50~14:30 Lobular Neoplasm ±è¾Ö¸®(°í·ÁÀÇ´ë)
±³À°½Ã°£ 11-23 ÀÓ»óÁ¦1,2°ÀÇ½Ç 14:30~15:10 Papillary Neoplasm ±Ç¿µ¹Ì(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 11-23 ÀÓ»óÁ¦1,2°ÀÇ½Ç 15:10~16:10 Fibroepithelial Tumor À¯ÇѼ®(¼¿ïÀÇ´ë)
±³À°½Ã°£ 11-23 ÀÓ»óÁ¦1,2°ÀÇ½Ç 16:10~16:50 Immune Microenvironment & PDL-1 IHC À̾ƿø(°¡Å縯ÀÇ´ë)